Search clinical trials for: LY03010

Total 32 results

Luye Pharma Group Ltd.

Enrolling by invitation

to Evaluate the Safety, Tolerability and Pharmacokinetics of Four Formulations of LY03009 in Healthy Volunteers

Parkinson's Disease

Australia
Luye Pharma Group Ltd.

Completed

A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subjects

Tardive Dyskinesia | Huntington Disease

China
Luye Pharma Group Ltd.

Completed

Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder

Mental Disorders | Psychotic Disorders | Mood Disorders | Schizophrenia | Schizophrenia Spectrum and Other Psychotic Disorders | Molecular Mechanisms of Pharmacological Action | Tranquilizing Agents | Physiological Effects of Drugs | Psychotropic Drugs | Antipsychotic Agents | Neurotransmitter Agents | Central...

United States
Luye Pharma Group Ltd.

Completed

Pharmacokinetic and Safety Study of LY03004 in Stable Patients With Schizophrenia or Schizoaffective Disorder (LY03004SAD)

Schizophrenia | Schizoaffective Disorder

United States
Luye Pharma Group Ltd.
Shandong Luye Pharmaceutical Co., Ltd.

Completed

Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LY03005 Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)

Major Depressive Disorder

China
Luye Pharma Group Ltd.

Completed

A Clinical Trial to Evaluate the Pharmacodynamics/Pharmacokinetics and Safety of LY03003 in Early PD Patients

Parkinson Disease

China
Luye Pharma Group Ltd.

Completed

A Study to Evaluate the Human Tolerance and Pharmacokinetics of LY03003

Parkinson Disease
Luye Pharma Group Ltd.

Completed

A Study to Evaluate the Pharmacokinetics and Safety of LY03003 in Patients With Advanced-stage PD

Parkinson Disease

China
Luye Pharma Group Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of Ansofaxine Hydrochloride Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)

Major Depressive Disorder (MDD)

China
Eli Lilly and Company

Completed

A Bioavailability Study of LY2452473 and Tadalafil

Erectile Dysfunction

United States
Luye Pharma Group Ltd.

Completed

Irinotecan Hydrochloride Liposome Injection (LY01610) For Advanced Solid Tumors

Advanced Solid Tumor

China
Luye Pharma Group Ltd.

Active, not recruiting

Irinotecan Hydrochloride Liposome Injection (LY01610) For Small Cell Lung Cancer

Small Cell Lung Cancer

China
Luye Pharma Group Ltd.

Completed

Pharmacokinetics and Safety Study of LY03003 in Patients With Early-stage Parkinson's Disease (03003MAD)

Parkinson's Disease

United States
Luye Pharma Group Ltd.

Completed

Relative Bioavailability of LY03010 Compared to Listed Drug

Mental Disorders | Psychotic Disorders | Mood Disorders | Schizophrenia | Molecular Mechanisms of Pharmacological Action | Tranquilizing Agents | Physiological Effects of Drugs | Psychotropic Drugs | Antipsychotic Agents | Central Nervous System Depressants | Neurotransmitter Agents | Schizophrenia Spectrum

United States
Luye Pharma Group Ltd.

Recruiting

Efficacy and Safety of LY01011 and Xgeva® in Patients With Bone Metastases From Solid Tumors

Bone Metastases From Solid Tumors

China
Luye Pharma Group Ltd.

Completed

Pharmacokinetic Study of LY03003 in Patients With Parkinson's Disease

Parkinson Disease

United States
Luye Pharma Group Ltd.

Completed

A Study to Assess Pharmacokinetic Profiles of LY03003 and Neupro

Parkinson Disease

United States
Luye Pharma Group Ltd.
Shang Dong Boan Biotechnology Co., Ltd (Co-sponsor)

Unknown

A Study to Evaluate LY01011 and Xgeva® in Healthy Adults

Healthy Adults
Shandong Boan Biotechnology Co., Ltd

Recruiting

A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Peking University Third Hospital

Completed

Efficacy and Safety of Rotigotine in the Treatment of Patients With Early Stage of Primary Parkinson's Disease

Parkinson's Disease

China
Luye Pharma Group Ltd.

Completed

A Study to Determine Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA® in Schizophrenia Patients

Schizophrenia | Schizoaffective Disorder | Schizo Affective Disorder

United States
Luye Pharma Group Ltd.
Beijing Bozhiyin T&S Co., Ltd.

Completed

A Multiple Ascending Dose Study With LY03003 in Patients With Early-stage Parkinson's Disease

Parkinson Disease

China
Luye Pharma Group Ltd.
Parexel

Completed

A Study to Evaluate the Effectiveness and Safety of LY03003 in Patients With Early Primary PD

Parkinson Disease

China
Luye Pharma Group Ltd.

Completed

Relative Bioavailability (RBA) Study of LY03005 vs Pristiq®

Major Depressive Disorder

United States
Luye Pharma Group Ltd.

Completed

Pilot BA Study of New LY03005 vs Pristiq

Major Depression

United States
Luye Pharma Group Ltd.

Completed

A Relative Bioavailability Food Effect Study of LY03005

Major Depressive Disorder

United States
Luye Pharma Group Ltd.

Completed

A Study of LY03005 vs Pristiq

Major Depressive Disorder

United States
Luye Pharma Group Ltd.

Completed

A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy Volunteers

Parkinson Disease

United States
Luye Pharma Group Ltd.

Completed

Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005

Major Depressive Disorder, Recurrent, Unspecified

United States
Luye Pharma Group Ltd.

Completed

An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder

Schizophrenia | Schizoaffective Disorder

United States
Luye Pharma Group Ltd.

Completed

Bioavailability of LY03004 and Risperdal® Consta®

Schizophrenia | Schizoaffective Disorder

United States
Luye Pharma Group Ltd.

Completed

Safety, Tolerability and Pharmacokinetics Study of LY03005 (LY03005SAD)

Major Depressive Disorder

United States

Search clinical trials for: LY03010

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Denmark

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations